Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18535817 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL3222729 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL661089 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL1015665 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL5831542 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL20758481 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL25382185 | 0.89 | PPM1D (0.35) | PPM1D | |
| SCHEMBL660447 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL5711228 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL5711230 | 0.89 | PPM1D (0.38) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020260857-A1 | HYDROXAMATE COMPOUNDS AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | AdoRx Therapeutics Limited (GB) | 2020-12-30 | — | — | WO | disclosed |
| EP-2727920-B1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-8841456-B2 | 1,5-naphthyridine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-09-23 | — | — | US | disclosed |
| US-20140142302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2014-05-22 | — | — | US | disclosed |
| EP-2727920-A1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | FUJIFILM Corporation (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2089368-B1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7652053-B2 | Diaminocycloalkane MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7115740-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1615928-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| WO-2004089955-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-10-14 | — | — | US | disclosed |
| WO-1996031476-A1 | AROMATIC HYDROXYETHERS | RHONE-POULENC RORER LIMITED (GB) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | PPM1D 1325/4885 |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | FGFR3, FGFR1, FGFR4 | PPM1D 932/4885 |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | NCOA4, PPARG, PPARA | PPM1D 4280/4885 |
| US-20140142302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | NRAS, RAF1, KRAS | PPM1D 142/4885 |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, NCOA4, PPARA | PPM1D 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.